Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
IBIO123 / Immune Biosolutions
NCT05639166: Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19	Completed	2	200	RoW	IBIO123, Placebo	Immune Biosolutions Inc	COVID-19	05/23	05/23
NCT05298813: Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness	Completed	1/2	162	RoW	IBIO123, Placebo	Immune Biosolutions Inc	COVID-19	01/23	01/23
NCT05303376: Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness	Completed	1/2	123	RoW	IBIO123, Placebo	Immune Biosolutions Inc	COVID-19	06/23	06/23
Undisclosed pancreatic cancer therapeutic / Immune Biosolutions
No trials found
Undisclosed ovarian cancer therapeutic / Immune Biosolutions
No trials found
neoantigen based therapeutic / Immune Biosolutions
No trials found